QA: Galectin Therapeutics INC in us_pharma/2011

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001133416_2012_Galectin_Therapeutics_INC.pdf

Logs

warning No LiabilitiesAndStockholdersEquity node found input.sec.calculation_linkbase.edgar_model_mapping {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'RestrictedCashAndCashEquivalentsNoncurrent', 'IntangibleAssetsNetExcludingGoodwill', 'CashAndCashEquivalentsAtCarryingValue', 'GrantsReceivableCurrent', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'OtherLiabilitiesNoncurrent', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'DividendsPayableCurrent', 'DeferredRevenueCurrent', 'WarrantLiabilitiesCurrent', 'UndesignatedCapitalStockValue', 'StockholdersEquity', 'PreferredStockValue', 'CommonStockValue', 'AdditionalPaidInCapital', 'DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage'))"}

Graph

Absolute values for 0001133416, Galectin Therapeutics INC

  xvar xval
0 AssetsCurrent 6,501,000
1 IntangibleAssetsNetIncludingGoodwill 36,000
2 PropertyPlantAndEquipmentNet 6,000
3 remainder_Assets 69,000
4 LiabilitiesCurrent 2,215,000
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 6,857,000
9 ResearchAndDevelopmentExpense 3,552,000
10 remainder_Expenses 0
11 remainder_Revenues 0
12 remainder_NetIncome -506,000
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 6,612,000
1 Liabilities 2,215,000
2 Expenses 10,409,000
3 Revenues 0
4 StockholdersEquity 4,397,000
5 NetIncome -10,915,000
6 ComprehensiveNetIncome -10,915,000
7 BaseVar 9,871,000
8 EconomicCapitalRatiobeforeLimitedLiability -0.301
9 EconomicCapitalRatio 1.40

Edgar->Model Mapping

Feature Distribution